Priority Date: 05.12.11 (US 201161566905P)

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3) DIRECTED TO DOMAIN II OF HER3

  • Application ID: EP12823094
  • Status: APPLICATION DEEMED TO BE WITHDRAWN

Applicant

Technology company logo small
Technology Company

Attorneys

no operation time available
1 office
Technology Company
no operation time available
1 office
Technology Company

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C07 (ORGANIC CHEMISTRY). Novartis Pharma AG is specialized in the combination A61 and C07. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB, df-mp Dörries Frank-Molnia & Pohlman, Patentanwälte Rechtsanwälte PartG mbB and 226 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 05.12.2011 - Priority Date (US 201161566905P)
  • 13.06.2013 - Publication A2 (WO2013084148)
  • 15.10.2014 - Publication A2 (EP2788382)

IPC Classification